BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

592 related articles for article (PubMed ID: 34916222)

  • 1. Activation of YAP1 by N6-Methyladenosine-Modified circCPSF6 Drives Malignancy in Hepatocellular Carcinoma.
    Chen Y; Ling Z; Cai X; Xu Y; Lv Z; Man D; Ge J; Yu C; Zhang D; Zhang Y; Xie H; Zhou L; Wu J; Zheng S
    Cancer Res; 2022 Feb; 82(4):599-614. PubMed ID: 34916222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ALKBH5 suppresses malignancy of hepatocellular carcinoma via m
    Chen Y; Zhao Y; Chen J; Peng C; Zhang Y; Tong R; Cheng Q; Yang B; Feng X; Lu Y; Xie H; Zhou L; Wu J; Zheng S
    Mol Cancer; 2020 Aug; 19(1):123. PubMed ID: 32772918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The functional roles, cross-talk and clinical implications of m6A modification and circRNA in hepatocellular carcinoma.
    Qin S; Mao Y; Chen X; Xiao J; Qin Y; Zhao L
    Int J Biol Sci; 2021; 17(12):3059-3079. PubMed ID: 34421350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CircCPSF6 promotes hepatocellular carcinoma cancer progression by regulating MAP4K4 through sponging miR-145-5p.
    Lu F; Gao J; Luo Y; Jin WL; Wang H; Li CX; Li X
    Mol Cell Probes; 2023 Oct; 71():101920. PubMed ID: 37442529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N6-methyladenosine-modified circTEAD1 stabilizes Yap1 mRNA to promote chordoma tumorigenesis.
    Li H; Tang Y; Ruan X; Zhang J; Liu H; Yu S; Chen H; Yang H; Zhang K; Chen K
    Clin Transl Med; 2024 Apr; 14(4):e1658. PubMed ID: 38659080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Prognostic Implications of Methylated RNA and Demethylases in Resected HCC and Background Liver Tissue.
    Nakagawa N; Tanaka K; Sonohara F; Kandimalla R; Sunagawa Y; Inokawa Y; Takami H; Hayashi M; Yamada S; Kanda M; Tanaka C; Nakayama G; Koike M; Kodera Y
    Anticancer Res; 2020 Dec; 40(12):6665-6676. PubMed ID: 33288560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RNA demethylase ALKBH5 prevents pancreatic cancer progression by posttranscriptional activation of PER1 in an m6A-YTHDF2-dependent manner.
    Guo X; Li K; Jiang W; Hu Y; Xiao W; Huang Y; Feng Y; Pan Q; Wan R
    Mol Cancer; 2020 May; 19(1):91. PubMed ID: 32429928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RNA m6A methylation promotes the formation of vasculogenic mimicry in hepatocellular carcinoma via Hippo pathway.
    Qiao K; Liu Y; Xu Z; Zhang H; Zhang H; Zhang C; Chang Z; Lu X; Li Z; Luo C; Liu Y; Yang C; Sun T
    Angiogenesis; 2021 Feb; 24(1):83-96. PubMed ID: 32920668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A positive-feedback loop between HBx and ALKBH5 promotes hepatocellular carcinogenesis.
    Qu S; Jin L; Huang H; Lin J; Gao W; Zeng Z
    BMC Cancer; 2021 Jun; 21(1):686. PubMed ID: 34112124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HBXIP drives metabolic reprogramming in hepatocellular carcinoma cells via METTL3-mediated m6A modification of HIF-1α.
    Yang N; Wang T; Li Q; Han F; Wang Z; Zhu R; Zhou J
    J Cell Physiol; 2021 May; 236(5):3863-3880. PubMed ID: 33305825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. WTAP facilitates progression of hepatocellular carcinoma via m6A-HuR-dependent epigenetic silencing of ETS1.
    Chen Y; Peng C; Chen J; Chen D; Yang B; He B; Hu W; Zhang Y; Liu H; Dai L; Xie H; Zhou L; Wu J; Zheng S
    Mol Cancer; 2019 Aug; 18(1):127. PubMed ID: 31438961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIF-1α-induced expression of m6A reader YTHDF1 drives hypoxia-induced autophagy and malignancy of hepatocellular carcinoma by promoting ATG2A and ATG14 translation.
    Li Q; Ni Y; Zhang L; Jiang R; Xu J; Yang H; Hu Y; Qiu J; Pu L; Tang J; Wang X
    Signal Transduct Target Ther; 2021 Feb; 6(1):76. PubMed ID: 33619246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circular RNA circDLC1 inhibits MMP1-mediated liver cancer progression via interaction with HuR.
    Liu H; Lan T; Li H; Xu L; Chen X; Liao H; Chen X; Du J; Cai Y; Wang J; Li X; Huang J; Yuan K; Zeng Y
    Theranostics; 2021; 11(3):1396-1411. PubMed ID: 33391541
    [No Abstract]   [Full Text] [Related]  

  • 14. M6A-mediated upregulation of circMDK promotes tumorigenesis and acts as a nanotherapeutic target in hepatocellular carcinoma.
    Du A; Li S; Zhou Y; Disoma C; Liao Y; Zhang Y; Chen Z; Yang Q; Liu P; Liu S; Dong Z; Razzaq A; Tao S; Chen X; Liu Y; Xu L; Zhang Q; Li S; Peng J; Xia Z
    Mol Cancer; 2022 May; 21(1):109. PubMed ID: 35524319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ALKBH5 regulates STAT3 activity to affect the proliferation and tumorigenicity of osteosarcoma via an m6A-YTHDF2-dependent manner.
    Yang Z; Cai Z; Yang C; Luo Z; Bao X
    EBioMedicine; 2022 Jun; 80():104019. PubMed ID: 35490460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KIAA1429 contributes to liver cancer progression through N6-methyladenosine-dependent post-transcriptional modification of GATA3.
    Lan T; Li H; Zhang D; Xu L; Liu H; Hao X; Yan X; Liao H; Chen X; Xie K; Li J; Liao M; Huang J; Yuan K; Zeng Y; Wu H
    Mol Cancer; 2019 Dec; 18(1):186. PubMed ID: 31856849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N
    Xu J; Wan Z; Tang M; Lin Z; Jiang S; Ji L; Gorshkov K; Mao Q; Xia S; Cen D; Zheng J; Liang X; Cai X
    Mol Cancer; 2020 Nov; 19(1):163. PubMed ID: 33222692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. YTHDF2 promotes the liver cancer stem cell phenotype and cancer metastasis by regulating OCT4 expression via m6A RNA methylation.
    Zhang C; Huang S; Zhuang H; Ruan S; Zhou Z; Huang K; Ji F; Ma Z; Hou B; He X
    Oncogene; 2020 Jun; 39(23):4507-4518. PubMed ID: 32366907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ALKBH5/YTHDF2-mediated m6A modification of circAFF2 enhances radiosensitivity of colorectal cancer by inhibiting Cullin neddylation.
    Shao Y; Liu Z; Song X; Sun R; Zhou Y; Zhang D; Sun H; Huang J; Wu C; Gu W; Zheng X; Jiang J
    Clin Transl Med; 2023 Jul; 13(7):e1318. PubMed ID: 37381158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CircRNA hsa_circRNA_104348 promotes hepatocellular carcinoma progression through modulating miR-187-3p/RTKN2 axis and activating Wnt/β-catenin pathway.
    Huang G; Liang M; Liu H; Huang J; Li P; Wang C; Zhang Y; Lin Y; Jiang X
    Cell Death Dis; 2020 Dec; 11(12):1065. PubMed ID: 33311442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.